However, this is a crude or simple cost-change calculation for three months of use of insulin and not an extensive cost analysis, and costs for hospitalisation due to hypoglycaemia and T2DM-related complications were not included in this study. This evidence concerns the gene INS and type 2 diabetes mellitus.